NCT06941792 - Inclisiran Effectiveness in China: a Pragmatic Randomized Trial | Biotech Hunter

Enrollment

1,590

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions

Coronary Heart Disease

Interventions

DRUG

inclisiran sodium injection

After randomization, patients in the inclisiran group will receive inclisiran sodium injection

COMBINATION_PRODUCT

Standard of Care

After randomization switching to or adding on another/other lipid-lowering therapies

Trial Locations (20)

102218

RECRUITING

Novartis Investigative Site, Beijing

110016

RECRUITING

Novartis Investigative Site, Shenyang

121100

RECRUITING

Novartis Investigative Site, Shenyang

154002

RECRUITING

Novartis Investigative Site, Jiamusi

200065

RECRUITING

Novartis Investigative Site, Shanghai

246003

RECRUITING

Novartis Investigative Site, Anqing

261000

RECRUITING

Novartis Investigative Site, Weifang

272000

RECRUITING

Novartis Investigative Site, Jining

310007

RECRUITING

Novartis Investigative Site, Hangzhou

315000

RECRUITING

Novartis Investigative Site, Ningbo

321000

RECRUITING

Novartis Investigative Site, Jinhua

325000

RECRUITING

Novartis Investigative Site, Wenzhou

NOT_YET_RECRUITING

Novartis Investigative Site, Wenzhou

364099

RECRUITING

Novartis Investigative Site, Longyan

400010

RECRUITING

Novartis Investigative Site, Chongqing

451400

RECRUITING

Novartis Investigative Site, Zhengzhou

610031

RECRUITING

Novartis Investigative Site, Chengdu

830054

RECRUITING

Novartis Investigative Site, Ürümqi

014010

RECRUITING

Novartis Investigative Site, Baotou

030000

RECRUITING

Novartis Investigated Site, Taiyuan